10x Genomics, Inc. (Nasdaq: TXG) today detailed a slew of new
products and announced the acquisition of Copenhagen-based Tetramer
Shop at its inaugural Xperience 2021 event, a showcase with three
breakout sessions corresponding to 10x’s three product
platforms: Chromium Single Cell, Visium Spatial, and In Situ
Analysis.
Tetramer Shop marks the fifth acquisition for 10x Genomics in
its ongoing mission to master biology to advance human health. This
acquisition follows the additions of epigenomics innovator
Epinomics and spatial genomics pioneer Spatial Transcriptomics in
2018, as well as In Situ analysis companies CartaNA AB and ReadCoor
in 2020. Tetramer Shop’s expertise in building empty, loadable MHC
molecules accelerates the development of TCR-based therapeutics and
diagnostics, broadening 10x Genomics immunology efforts. Terms of
the deal were not disclosed.
Tetramer Shop was founded by Søren Jakobsen, Professors Sine
Hadrup and Sunil Kumar from Danish Technical University, and
Professor Sebastian Springer from Jacobs University. They are
pioneers in the antigen-TCR discovery space, having previously
developed technologies in this area. 10x Genomics will add to
its European research efforts with a center in Copenhagen that
Søren will lead. Sine, Sunil and Sebastian plan to continue to
support 10x as advisors.
“Tetramer Shop will enable our customers to accelerate the
development of TCR-based therapeutics and diagnostics that are
critical to immunology, and we are thrilled to have them join
forces with us,” said Ben Hindson, 10x Genomics Co-founder and
Chief Scientific Officer.
Upcoming products detailed at Xperience 2021 followed their
initial reveal last month at the annual J.P. Morgan Health
Conference. New capabilities for single-cell analysis were
featured, including:
- Low Throughput (LT) Single Cell Gene Expression
solution - Enabling proof of concept before scaling, this
kit will democratize single-cell sequencing by lowering startup
costs by up to 60 percent. It is expected to ship in the first half
of 2021.
- CellPlex Kit - Cell Multiplexing allows for
increased sample and cell throughput as multiple samples and higher
cell loads can be loaded into each channel. Seen as a way to lower
costs for labs and increase adoption of the Chromium platform, it
is expected to arrive in Q1 2021.
- Chromium X - This next generation single-cell
instrument will make experiments of up to one million cells
routine. It is expected to ship in the second half of
2021.
- Fixed RNA Profiling Kit - Offering whole
transcriptome and targeted based readouts, this product addresses
sample preparation challenges by preserving cell/sample integrity
and the need to process samples in batches and transport samples.
The company expects it to launch in the second half of 2021.
- Barcode Enabled Antigen Mapping (BEAM)
Solution - Provides an end-to-end solution for the
high-throughput discovery of antibodies and T cell receptors
against multiple antigens in a week. The product, targeted at
biotech and pharmaceutical companies, is expected to launch in the
first half of 2022.
Continuing its commitment to leading the way in spatial
analysis, 10x also shared closer looks at three new capabilities
that will be coming to its Visium platform over the next 18
months:
- Visium for FFPE - Removing the need for an
expensive dedicated instrument, Visium for FFPE will allow
researchers to measure gene expression across an entire tissue that
has been formalin-fixed paraffin-embedded without having to
pre-select regions of interest. It is the first technology to
enable true discovery in FFPE samples, delivering the full
transcriptome across the entire tissue with sensitivity on par with
analyzing fresh tissues with standard Visium. It is expected to
ship in Q2 of 2021.
- Visium Highly Multiplexed Protein - This new
offering enables high-plexy spatial multiomic readouts on the same
tissue section with one workflow for a next-gen sequencing
readout. It is expected to be available starting the second
half of 2021.
- Visium CytAssist - A benchtop instrument
intended to facilitate the simple and rapid capture of fresh or
archived tissue sections for analysis, CytAssist will enable users
to stain and pre-screen tissue sections mounted on standard
microscopy slides prior to gene or protein expression analysis with
Visium assays. It is expected to arrive in the first half of
2022.
- Visium HD - This revolutionary product will
get spatial transcriptomics to its ultimate goal of single-cell
resolution with 400x times the resolution of the current Visium
solution for both FFPE and fresh frozen samples with whole
transcriptome, targeted, and highly multiplexed protein assays. It
is expected to be available in the first half of 2022.
Finally, 10x announced the US launch of its 10x Genomics Cloud
Analysis, a fast, easy-to-use, and scalable platform for data
analysis to all of its customers which offers a standard set of
analyses at no additional cost for every sample purchased. The 10x
Cloud will enable new users to get started more rapidly on their
experiments and allow advanced users to scale to larger and more
complex ones. The company also outlined its roadmap to bring new
applications, new visualizations, and support for additional
regions around the globe.
“Xperience 2021 is a fantastic way for us to share a view of our
future roadmap in a way we’ve never done before,” continued
Hindson. “The products and capabilities we showcased today
represent some of our most innovative work to date, and we hope
they will empower scientists to make new discoveries in
biology.”
To learn more about products showcased at Xperience 2021, please
visit http://www.10xgenomics.com/xperience2021. The
event will also be hosted on March 3 for the Asia Pacific region,
and registration is open
at https://www.10xgenomics.com/xperience-apac.
About 10x Genomics10x Genomics
is a life science technology company building products to
interrogate, understand and master biology to advance human health.
The company’s integrated solutions include instruments, consumables
and software for analyzing biological systems at a resolution and
scale that matches the complexity of biology. 10x Genomics products
have been adopted by researchers around the world including in all
of the top 100 global research institutions as ranked by Nature in
2019 based on publications and all of the top 20 global
pharmaceutical companies by 2019 research and development spend,
and have been cited in over 2,200 research papers on discoveries
ranging from oncology to immunology and neuroscience. The company’s
patent portfolio comprises more than 1,000 issued patents and
patent applications.
Forward Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 as
contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to the “safe harbor” created by those sections.
All statements, other than statements of historical facts, may be
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negatives
of these terms or variations of them or similar terminology, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding 10x Genomics, Inc.’s expectations regarding
the company’s business operations, financial performance and
results of operations as well as the company’s ability to meet its
anticipated cash needs for the foreseeable future. These statements
are based on management’s current expectations, forecasts, beliefs,
assumptions and information currently available to management, and
actual outcomes and results could differ materially from these
statements due to a number of factors, including the potential
impact of the COVID-19 pandemic. Other risks and uncertainties that
could affect 10x Genomics, Inc.’s financial and operating results
and cause actual results to differ materially from those indicated
by the forward-looking statements made in this press release
include those discussed under the captions “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” and elsewhere in the documents 10x Genomics,
Inc. files with the Securities and Exchange Commission from time to
time. Although 10x Genomics, Inc. believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot provide any assurance that these expectations will prove to
be correct nor can it guarantee that the future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. These
forward-looking statements do not reflect the potential impact of
any future acquisitions, mergers, dispositions, joint ventures or
investments 10x Genomics may make. Further, as the COVID-19
pandemic is unprecedented and continuously evolving, such
forward-looking statements may not accurately or fully reflect the
potential impact that the COVID-19 pandemic may have on the
business, financial condition, results of operations and cash flows
of 10x Genomics, Inc. The forward-looking statements in this press
release are based on information available to 10x Genomics, Inc. as
of the date hereof, and 10x Genomics, Inc. disclaims any obligation
to update any forward-looking statements provided to reflect any
change in its expectations or any change in events, conditions, or
circumstances on which any such statement is based, except as
required by law. These forward- looking statements should not be
relied upon as representing 10x Genomics, Inc.’s views as of any
date subsequent to the date of this press release.
Disclosure Information10x
Genomics uses filings with the Securities and Exchange Commission,
its website (www.10xgenomics.com), press releases, public
conference calls, public webcasts and its social media accounts as
means of disclosing material non-public information and for
complying with its disclosure obligations under Regulation FD.
ContactsMedia:media@10xgenomics.comInvestors:investors@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Apr 2023 to Apr 2024